Back to top
more

NuVasive, Inc. (NUVA)

(Delayed Data from NSDQ)

$62.96 USD

62.96
567,418

+0.74 (1.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $62.96 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Why NuVasive (NUVA) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

NuVasive (NUVA) Q2 Earnings Meet Estimates, Margins Down

NuVasive's (NUVA) second-quarter 2023 results reflect the robust performance of the U.S. Cervical business.

NuVasive (NUVA) Q2 Earnings Meet Estimates

NuVasive (NUVA) delivered earnings and revenue surprises of 0% and 1.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

NuVasive (NUVA) Q1 Earnings Beat Estimates, Margins Fall

NuVasive's (NUVA) strong sales across the U.S. Spinal Hardware and U.S. Surgical Support businesses instill optimism.

NuVasive (NUVA) Tops Q1 Earnings and Revenue Estimates

NuVasive (NUVA) delivered earnings and revenue surprises of 14.63% and 3.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

AdaptHealth Corp. (AHCO) Q1 Earnings and Revenues Lag Estimates

AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -87.50% and 2.03%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Is NuVasive (NUVA) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

New Strong Buy Stocks for April 26th

EGY, MSGS, NUVA, NWG and VCISY have been added to the Zacks Rank #1 (Strong Buy) List on April 26, 2022.

NUVA vs. ABT: Which Stock Is the Better Value Option?

NUVA vs. ABT: Which Stock Is the Better Value Option?

Are Investors Undervaluing Baxter International (BAX) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Is NuVasive (NUVA) Down 15.9% Since Last Earnings Report?

NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NuVasive's (NUVA) Precice System Cleared for Pediatric Patients

NuVasive (NUVA) receives FDA 510(k) clearance for using the Precice limb lengthening system for treating pediatric patients.

NuVasive (NUVA), GMED Merger Aids, Macro Woes Mar Growth

According to NuVasive (NUVA), the combined company is set to have an advanced commercial scale and portfolio of clinically proven solutions.

Lantheus and NuVasive have been highlighted as Zacks Bull and Bear of the Day

Lantheus and NuVasive have been highlighted as Zacks Bull and Bear of the Day.

Kevin Cook headshot

Bear of the Day: NuVasive (NUVA)

Softer results for spinal surgery innovator plus questionable merger have dropped estimates and shares

NuVasive (NUVA) Q4 Earnings Miss Estimates, Margins Down

Inflationary costs, supply chain disruptions, volatility in foreign exchange rates and the persistent COVID-led impact hurt NuVasive's (NUVA) Q4 revenues.

NuVasive (NUVA) Q4 Earnings and Revenues Miss Estimates

NuVasive (NUVA) delivered earnings and revenue surprises of -12.24% and 1.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates

Bio-Rad (BIO) delivered earnings and revenue surprises of -4.06% and 2.93%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

NuVasive (NUVA) Suffers From Macro Headwinds, Price Issue

NuVasive (NUVA) believes that its 2022 guidance is appropriately conservative, considering macroeconomic pressures on net sales and operating profit.

Why Is Medtronic (MDT) Down 2.4% Since Last Earnings Report?

Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NuVasive (NUVA) Q3 Earnings Beat Estimates, Guidance Cut

The continued demand for NuVasive's (NUVA) Simplified Cervical Disc is encouraging.

NuVasive (NUVA) Surpasses Q3 Earnings Estimates

NuVasive (NUVA) delivered earnings and revenue surprises of 1.89% and 0.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Can Cigna's (CI) Q3 Earnings Beat on Evernorth Performance?

The third-quarter results of Cigna (CI) are likely to reflect a rise in total medical customers.

NuVasive (NUVA) Reports Next Week: Wall Street Expects Earnings Growth

NuVasive (NUVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.